Affinity Asset Advisors, LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Affinity Asset Advisors, LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$38.96 - $42.75 $7.79 Million - $8.55 Million	200,000 Added 66.67%	500,000 $20.4 Million
Q1 2024 May 14, 2024	SELL	$40.88 - $43.27 $18.4 Million - $19.5 Million	-450,000 Reduced 60.0%	300,000 $12.7 Million
Q4 2023 Feb 13, 2024	BUY	$20.27 - $42.44 $1.32 Million - $2.76 Million	64,939 Added 9.48%	750,000 $31.8 Million
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $2.74 Million - $4.31 Million	135,061 Added 24.56%	685,061 $15 Million
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $4.06 Million - $6.01 Million	170,000 Added 44.74%	550,000 $17.5 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $3.77 Million - $5.83 Million	165,000 Added 76.74%	380,000 $9.27 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $5.45 Million - $6.87 Million	215,000 New	215,000 $6.78 Million
Q2 2022 Aug 12, 2022	SELL	$20.62 - $37.15 $1.44 Million - $2.6 Million	-70,000 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$23.5 - $35.38 $3.64 Million - $5.48 Million	-155,000 Reduced 68.89%	70,000 $2.45 Million
Q4 2021 Feb 11, 2022	SELL	$29.21 - $44.64 $1.02 Million - $1.56 Million	-34,966 Reduced 13.45%	225,000 $7.3 Million
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $1.27 Million - $2.33 Million	59,966 Added 29.98%	259,966 $7.67 Million
Q2 2021 Aug 13, 2021	SELL	$12.56 - $29.69 $879,200 - $2.08 Million	-70,000 Reduced 25.93%	200,000 $5.12 Million
Q4 2020 Feb 12, 2021	BUY	$9.82 - $18.27 $2.65 Million - $4.93 Million	270,000 New	270,000 $4.48 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Affinity Asset Advisors, LLC with notifications on news.